We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Product type
Topic
- (-) Scheduling (national classification system) (27)
- Advertising (272)
- COVID-19 (163)
- Safety monitoring and information (96)
- Legislation (93)
- Compliance and enforcement (65)
- Manufacturing (52)
- Vaping hub (51)
- Labelling and packaging (35)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
115 result(s) found, displaying 26 to 50
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has published a final decision to reduce the maximum size of packs for various paracetamol products.
-
Media releasesFrom 1 June 2023, prescribing of oral ivermectin for ‘off-label’ uses will no longer be limited to specialists such as dermatologists, gastroenterologists and infectious diseases specialists.
-
Media releasesThe TGA has approved Moderna Australia’s application to transition its COVID-19 vaccine, SPIKEVAX (elasomeran), from provisional to full registration.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
BlogFrom 1 July 2023, authorised psychiatrists can prescribe psychedelic medicines to people with specific mental health conditions under strict controls.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Regulatory decision noticesThis instrument is made under section 39 of the current Poisons Standard.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesOn 17 February, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine. This is the second bivalent vaccine targeting the Omicron BA.4-5 subvariants that has been provisionally approved by the TGA
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has today published an interim decision to reduce the maximum pack sizes for various paracetamol products.
-
Media releasesFrom 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThis is the first vaccine provisionally approved by the TGA that is designed to specifically target the Omicron variants BA.4/BA.5 and follows provisional approval of the Pfizer BA.1 Omicron/original bivalent vaccine.
-
Media releasesThe TGA has commenced evaluation of an application from Moderna Australia Pty Ltd to transition its COVID-19 vaccine, SPIKEVAX, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has granted a provisional determination to Pfizer's bivalent COVID-19 vaccine candidate: tozinameran & famtozinameran (COMIRNATY BIVALENT OMICRON BA.4/BA.5 COVID-19 VACCINE).